Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Synairgen Plc (SNG.LN)

Synairgen Plc (SNG.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19 Business Wire - Tue Oct 4, 2022

Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta to treat or prevent severe...

SNG.LN : 6.200 (+1.31%)
Synairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022 Business Wire - Tue Sep 20, 2022

Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces it will...

SNG.LN : 6.200 (+1.31%)
Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patients Business Wire - Wed Sep 7, 2022

Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces positive...

SNG.LN : 6.200 (+1.31%)
Synairgen Presents Detailed Analysis of Phase 3 SPRINTER Trial Evaluating SNG001 in Hospitalised COVID-19 Patients at ATS 2022 Business Wire - Mon May 16, 2022

Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first...

SNG.LN : 6.200 (+1.31%)
Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Globe Newswire - Wed Oct 20, 2021

Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2...

SNG.LN : 6.200 (+1.31%)
Interim results for the six months ended 30 June 2021 Globe NewsWire - Thu Sep 30, 2021

Synairgen plc (‘Synairgen’ or the ‘Company’)

SNG.LN : 6.200 (+1.31%)
Non-Executive Director Appointment Globe NewsWire - Thu Sep 30, 2021

Synairgen plc (‘Synairgen’ or the ‘Company’)

SNG.LN : 6.200 (+1.31%)
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants Globe NewsWire - Mon May 24, 2021

Press release

SNG.LN : 6.200 (+1.31%)
Preliminary results for the year ended 31 December 2020 Globe NewsWire - Wed May 12, 2021

Press release

SNG.LN : 6.200 (+1.31%)
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial Globe NewsWire - Fri Apr 30, 2021

Press release

SNG.LN : 6.200 (+1.31%)

Barchart Exclusives

Will This EV Stock Burn Short Sellers Like Tesla Did With Its Q1 Earnings Report? Barchart - 15 minutes ago
Rivian will release its Q1 earnings after the bell this Tuesday, May 7. The setup for the EV startup looks good heading into the release, which could set the stage for a post-earnings rebound like we saw with Tesla. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot